Cargando…
Prognosis of ampullary cancer based on immunohistochemical type and expression of osteopontin
BACKGROUND: Ampullary cancer (AC) was classified as pancreatobiliary, intestinal, or other subtype based on the expression of cytokeratin 7 (CK7) and cytokeratin 20 (CK20). We aimed to explore the association of AC subtype with patient prognosis. METHODS: The relationship of AC subtype and expressio...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3213044/ https://www.ncbi.nlm.nih.gov/pubmed/21992455 http://dx.doi.org/10.1186/1746-1596-6-98 |
_version_ | 1782216067567845376 |
---|---|
author | Zhao, Xiang-qian Dong, Jia-hong Zhang, Wen-zhi Liu, Zhe |
author_facet | Zhao, Xiang-qian Dong, Jia-hong Zhang, Wen-zhi Liu, Zhe |
author_sort | Zhao, Xiang-qian |
collection | PubMed |
description | BACKGROUND: Ampullary cancer (AC) was classified as pancreatobiliary, intestinal, or other subtype based on the expression of cytokeratin 7 (CK7) and cytokeratin 20 (CK20). We aimed to explore the association of AC subtype with patient prognosis. METHODS: The relationship of AC subtype and expression of Osteopontin (OPN) with the prognosis of 120 AC patients after pancreaticoduodenectomy was investigated. RESULTS: The patients had pancreatobiliary (CK7(+)/CK20(-), n = 24, 20%), intestinal (CK7(-)/CK20(+), n = 29, 24.2%) or other (CK7(+)/CK20(+ )or CK7(-)/CK20(-), n = 67, 55.8%) subtypes of AC, and their median survival times were 23 ± 4.2, 38 ± 2.8 and 64 ± 16.8 months, respectively. The survival times of 64 OPN(- )patients (53.3%) and 56 OPN(+ )patients (46.7%) were 69 ± 18.4 and 36 ± 1.3 months, respectively. There was no significant effect of AC subtype on survival of OPN(- )patients. For OPN(+ )patients, those with pancreatobiliary AC had a shorter survival time (22 ± 6.6 months) than those with intestinal AC (37 ± 1.4 months, p = 0.041), and other AC subtype (36 ± 0.9 months, p = 0.010); intestinal and other AC subtypes had similar survival times. CONCLUSIONS: The prognosis of AC patients can be estimated based on immunohistochemical classification and OPN status. |
format | Online Article Text |
id | pubmed-3213044 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-32130442011-11-11 Prognosis of ampullary cancer based on immunohistochemical type and expression of osteopontin Zhao, Xiang-qian Dong, Jia-hong Zhang, Wen-zhi Liu, Zhe Diagn Pathol Research BACKGROUND: Ampullary cancer (AC) was classified as pancreatobiliary, intestinal, or other subtype based on the expression of cytokeratin 7 (CK7) and cytokeratin 20 (CK20). We aimed to explore the association of AC subtype with patient prognosis. METHODS: The relationship of AC subtype and expression of Osteopontin (OPN) with the prognosis of 120 AC patients after pancreaticoduodenectomy was investigated. RESULTS: The patients had pancreatobiliary (CK7(+)/CK20(-), n = 24, 20%), intestinal (CK7(-)/CK20(+), n = 29, 24.2%) or other (CK7(+)/CK20(+ )or CK7(-)/CK20(-), n = 67, 55.8%) subtypes of AC, and their median survival times were 23 ± 4.2, 38 ± 2.8 and 64 ± 16.8 months, respectively. The survival times of 64 OPN(- )patients (53.3%) and 56 OPN(+ )patients (46.7%) were 69 ± 18.4 and 36 ± 1.3 months, respectively. There was no significant effect of AC subtype on survival of OPN(- )patients. For OPN(+ )patients, those with pancreatobiliary AC had a shorter survival time (22 ± 6.6 months) than those with intestinal AC (37 ± 1.4 months, p = 0.041), and other AC subtype (36 ± 0.9 months, p = 0.010); intestinal and other AC subtypes had similar survival times. CONCLUSIONS: The prognosis of AC patients can be estimated based on immunohistochemical classification and OPN status. BioMed Central 2011-10-13 /pmc/articles/PMC3213044/ /pubmed/21992455 http://dx.doi.org/10.1186/1746-1596-6-98 Text en Copyright ©2011 Zhao et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Zhao, Xiang-qian Dong, Jia-hong Zhang, Wen-zhi Liu, Zhe Prognosis of ampullary cancer based on immunohistochemical type and expression of osteopontin |
title | Prognosis of ampullary cancer based on immunohistochemical type and expression of osteopontin |
title_full | Prognosis of ampullary cancer based on immunohistochemical type and expression of osteopontin |
title_fullStr | Prognosis of ampullary cancer based on immunohistochemical type and expression of osteopontin |
title_full_unstemmed | Prognosis of ampullary cancer based on immunohistochemical type and expression of osteopontin |
title_short | Prognosis of ampullary cancer based on immunohistochemical type and expression of osteopontin |
title_sort | prognosis of ampullary cancer based on immunohistochemical type and expression of osteopontin |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3213044/ https://www.ncbi.nlm.nih.gov/pubmed/21992455 http://dx.doi.org/10.1186/1746-1596-6-98 |
work_keys_str_mv | AT zhaoxiangqian prognosisofampullarycancerbasedonimmunohistochemicaltypeandexpressionofosteopontin AT dongjiahong prognosisofampullarycancerbasedonimmunohistochemicaltypeandexpressionofosteopontin AT zhangwenzhi prognosisofampullarycancerbasedonimmunohistochemicaltypeandexpressionofosteopontin AT liuzhe prognosisofampullarycancerbasedonimmunohistochemicaltypeandexpressionofosteopontin |